RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/36271147http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/36271147http://www.w3.org/2000/01/rdf-schema#comment"CD40 signaling in classical type 1 dendritic cells (cDC1s) is required for CD8 T cell-mediated tumor rejection, but the underlying mechanisms are incompletely understood. Here, we identified CD40-induced genes in cDC1s, including Cd70, Tnfsf9, Ptgs2 and Bcl2l1, and examined their contributions to anti-tumor immunity. cDC1-specific inactivation of CD70 and COX-2, and global CD27 inactivation, only partially impaired tumor rejection or tumor-specific CD8 T cell expansion. Loss of 4-1BB, alone or in Cd27-/- mice, did not further impair anti-tumor immunity. However, cDC1-specific CD40 inactivation reduced cDC1 mitochondrial transmembrane potential and increased caspase activation in tumor-draining lymph nodes, reducing migratory cDC1 numbers in vivo. Similar impairments occurred during in vitro antigen presentation by Cd40-/- cDC1s to CD8+ T cells, which were reversed by re-expression of Bcl2l1. Thus, CD40 signaling in cDC1s not only induces costimulatory ligands for CD8+ T cells but also induces Bcl2l1 that sustains cDC1 survival during priming of anti-tumor responses."xsd:string
http://purl.uniprot.org/citations/36271147http://purl.org/dc/terms/identifier"doi:10.1038/s41590-022-01324-w"xsd:string
http://purl.uniprot.org/citations/36271147http://purl.uniprot.org/core/author"Anderson D.A."xsd:string
http://purl.uniprot.org/citations/36271147http://purl.uniprot.org/core/author"Kim S."xsd:string
http://purl.uniprot.org/citations/36271147http://purl.uniprot.org/core/author"Wu R."xsd:string
http://purl.uniprot.org/citations/36271147http://purl.uniprot.org/core/author"Jo S."xsd:string
http://purl.uniprot.org/citations/36271147http://purl.uniprot.org/core/author"Liu T.T."xsd:string
http://purl.uniprot.org/citations/36271147http://purl.uniprot.org/core/author"Murphy K.M."xsd:string
http://purl.uniprot.org/citations/36271147http://purl.uniprot.org/core/author"Murphy T.L."xsd:string
http://purl.uniprot.org/citations/36271147http://purl.uniprot.org/core/author"Schreiber R.D."xsd:string
http://purl.uniprot.org/citations/36271147http://purl.uniprot.org/core/author"Wong B.W."xsd:string
http://purl.uniprot.org/citations/36271147http://purl.uniprot.org/core/author"Theisen D.J."xsd:string
http://purl.uniprot.org/citations/36271147http://purl.uniprot.org/core/author"Gershon T."xsd:string
http://purl.uniprot.org/citations/36271147http://purl.uniprot.org/core/author"Ferris S.T."xsd:string
http://purl.uniprot.org/citations/36271147http://purl.uniprot.org/core/author"Ohara R.A."xsd:string
http://purl.uniprot.org/citations/36271147http://purl.uniprot.org/core/author"Ou F."xsd:string
http://purl.uniprot.org/citations/36271147http://purl.uniprot.org/core/date"2022"xsd:gYear
http://purl.uniprot.org/citations/36271147http://purl.uniprot.org/core/name"Nat Immunol"xsd:string
http://purl.uniprot.org/citations/36271147http://purl.uniprot.org/core/pages"1536-1550"xsd:string
http://purl.uniprot.org/citations/36271147http://purl.uniprot.org/core/title"Mechanisms of CD40-dependent cDC1 licensing beyond costimulation."xsd:string
http://purl.uniprot.org/citations/36271147http://purl.uniprot.org/core/volume"23"xsd:string
http://purl.uniprot.org/citations/36271147http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/36271147
http://purl.uniprot.org/citations/36271147http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/36271147
http://purl.uniprot.org/uniprot/#_A0A087WPT2-mappedCitation-36271147http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/36271147